Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024


Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis

Go here to read the rest:
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024

Related Posts